NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

09 Aug 2019
Jonsson Comprehensive Cancer Center and National Cancer Institute withdraw UCLA SPORE 1 Project, a phase II Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma) in USA prior to enrolment (Parenteral) (NCT03014804)

September 4th. 2019
Kevin Duffy, Specialist in Immuno-Oncology; Previously Research Scientific Director In Merck’s Keytruda® Program, joins a below 20 employees NWBO.

December 17th. 2019
UCLA SPORE 1 Project, Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma, the combo trial with DCVax-L and Keytruda, first posted at ClinicalTrials.gov


6-9 months later in 2020.
Kevin Duffy leaves NWBO

ATLnsider also do not believe this was a "coincidence".

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167958321

Let's face it. You do not have coincidences, where the top dog of Keytruda from Merck joins a less than 20 employee small biotech with two agents in pipeline and few months before UCLA stops their top combo trial project with DCVax and Opdivo from BMY and few months after Kevin Duffy joined, the UCLA SPORE 1 project starts up, with Keytruda instead.

By the way. The clinical trial of the combo trial last updated on ClinicalTrials.gov same date as Linda Liau presented about it March 31st.